- Users can connect, reconnect and disconnect even when flow path is wet and pressurized
- New Lynx® CDR connectors facilitate faster and more economic biopharma fluid management
DARMSTADT, Germany, April 26, 2016 /PRNewswire/ -- Merck, a leading science and technology company, today announced the launch of its first-in-class Lynx® CDR connectors to improve fluid management in the biopharma industry. The Lynx® CDR connectors debut at the International Pharmaceutical Expo (INTERPHEX) event in New York, New York, April 26-28.
"Lynx® CDR connectors will change the way pharmaceutical fluids are managed, lowering drug manufacturing costs," said Udit Batra, CEO, Life Science at Merck. "The Lynx® CDR connectors set a new standard for sterile fluid connections, dramatically improving ease of use and reliability."
Making simple, reliable, sterile-to-sterile fluid connections is critical to successful biomanufacturing. Previous disposable connector technology allowed users to make only a single sterile connection per device, requiring the use of multiple devices per unit operation. Previous technology also required a dry, non-pressurized flow path during connection and disconnection. These limitations are resource- and cost-intensive when industry standards demand increased productivity and improved efficiency at all stages of the drug manufacturing process. With the Lynx® CDR connectors, users can perform faster, more economic fluid management when the flow path is wet and pressurized.
Lynx® CDR connectors allow efficient fluid management through sterile connection, disconnection and reconnection giving customers a fail-safe alternative to the time-consuming tube welding processes and costly manifold configurations traditionally used in upstream and downstream processing. The connectors provide efficient fluid management with six sterile connections, disconnections and reconnections from one disposable device.
INTERPHEX attendees should visit booth #2841 to learn more about Merck's products and speak with company experts. Follow us on Twitter @merckgroup.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of €12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.